SAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade") (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced new preclinical data on JADE101, its anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy (IgAN), will be presented in an oral session during the 62nd European Renal Association (ERA) Congress, taking place in Vienna from June 4-7, 2025. The presentation, titled "Discovery and Characterization of JADE101, an Ultra-High Affinity, Half-Life Extended Anti-APRIL Monoclonal Antibody for the Treatment of IgAN," will be delivered

Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to enter the clinic in second half of 2025, with interim biomarker-rich data expected in first half of 2026 SAN FRANCISCO and VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade") (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the quarter ending March 31, 2025, and provided a corporate update. "The start to 2025 marked a defining period for Jade Biosciences

SAN FRANCISCO and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade"), (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the Jefferies Global Healthcare Conference, June 3-5, 2025, in New York.   Tom Frohlich, Chief Executive Officer of Jade, will deliver a company presentation on Wednesday, June 4 at 4:55-5:25 p.m. ET. Members of the management team will also host investor meetings during the conference. Investors and the general public are invited to listen to the session by visiting the Investors and Media page on JadeBiosciences.com. An archived e

SAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade") (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced new preclinical data on JADE101, its anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy (IgAN), will be presented in an oral session during the 62nd European Renal Association (ERA) Congress, taking place in Vienna from June 4-7, 2025. The presentation, titled "Discovery and Characterization of JADE101, an Ultra-High Affinity, Half-Life Extended Anti-APRIL Monoclonal Antibody for the Treatment of IgAN," will be delivered